

Supplementary Table S-2. Number of subject with reported medication among the SLE patients, matched controls, and the aPL+ and SSA/SSB+ SLE subgroups. Bonferroni corrected p-values < 0.05 are highlighted in bold.

	Controls n=316 Median (IQR) ¹	SLE n=378 Median (IQR) ¹	aPL+ SLE n=66 Median (IQR) ¹	SSA/SSB+ SLE n=63 Median (IQR) ¹	Ctrl vs. aPL+ SLE p-value ²	Ctrl vs. SSA/SSB+ SLE p-value ²	aPL+ vs. SSA/SSB+ SLE p-value ²
Medication							
Acetylsalicylic Acid	3	2	0	0	-	-	-
Azathioprin	0	51	11	5	8.9E-09	1.5E-04	1.2E-01
Calcichew	3	35	6	5	1.8E-03	5.5E-03	7.6E-01
Cyclophosphamide	0	1	0	0	-	-	-
D vitamin	15	198	37	29	1.6E-19	3.7E-16	4.8E-01
Esomeprazol	2	10	2	1	1.5E-01	4.3E-01	1.0E+00
Folic Acid	1	24	6	2	2.0E-04	7.7E-02	2.7E-01
Furosemide	1	26	4	1	4.3E-03	3.1E-01	3.7E-01
Hydroxychloroquine	0	67	9	12	2.3E-07	1.2E-09	8.1E-01
Ibuprofen	4	13	4	3	3.9E-02	1.0E-01	1.0E+00
Karbamazepin	0	4	0	1	-	1.7E-01	4.9E-01
Levothyroxine	20	43	6	8	6.0E-01	2.0E-01	7.8E-01
Methotrexate	0	11	2	0	3.1E-02	1.0E+00	5.0E-01
Mycophenolate	0	27	3	3	5.6E-03	5.0E-03	1.0E+00
Paracetamol	12	59	7	9	6.3E-02	7.1E-03	8.0E-01
Rituximab	0	26	7	4	4.8E-09	3.7E-06	2.1E-01
SNRI	3	5	1	1	2.5E-02	2.5E-02	5.8E-02
SSRI	12	27	7	4	1.7E-06	2.5E-04	1.4E-02
Warfarin	1	39	21	5	2.4E-14	8.0E-04	3.8E-04